LAVA Therapeutics NV has announced a change in its certifying accountants, appointing KPMG LLP as its new independent registered public accounting firm for the fiscal year ending December 31, 2025. This decision follows the dismissal of PricewaterhouseCoopers Accountants N.V. (PwC), which had previously audited the company's financial statements for 2023 and 2024. PwC's reports during these years contained no adverse opinions or disclaimers. However, the company had identified material weaknesses in its internal controls over financial reporting, specifically related to inadequate general controls over information technology and segregation of duties. These issues were successfully remediated by the end of 2024, as reported in their Annual Report filed in March 2025. PwC had discussed these matters with LAVA's Audit Committee, and the company has permitted PwC to fully inform KPMG about these past issues.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。